HC Wainwright Raises Earnings Estimates for CalciMedica

CalciMedica Inc. (NASDAQ:CALC) – HC Wainwright lifted their FY2026 earnings estimates for CalciMedica in a research note issued to investors on Tuesday, November 10th. HC Wainwright analyst J. Pantginis now anticipates that the company will post earnings of ($1.93) per share for the year, up from their prior estimate of ($5.25). HC Wainwright has a “Neutral” rating on the stock. The consensus estimate for CalciMedica’s current full-year earnings is ($5.25) per share. HC Wainwright also issued estimates for CalciMedica’s Q4 2026 earnings at ($0.41) EPS, FY2027 earnings at ($1.61) EPS and FY2028 earnings at ($1.93) EPS.

CalciMedica (NASDAQ:CALC) last announced its quarterly earnings results on Tuesday, November 10th. The company reported ($0.24) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.27) by $1.03.

Several other research analysts also recently issued reports on CALC. UBS Group restated a “neutral” rating on shares of CalciMedica in a research report on Thursday, August 13th. Wall Street Zen cut CalciMedica from a “sell” rating to a “strong sell” rating in a report on Saturday, September 12th. Guggenheim assumed coverage on CalciMedica in a research report on Thursday, August 20th. They set a “buy” rating for the company. Finally, Weiss Ratings raised CalciMedica from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, August 27th. Two investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $50.00.

CalciMedica Trading Down 9.5%

Shares of CALC opened at $1.24 on Thursday. The company has a debt-to-equity ratio of 1.67, a current ratio of 5.58 and a quick ratio of 5.58. The firm has a 50 day simple moving average of $1.57 and a 200-day simple moving average of $3.25. CalciMedica has a 1-year low of $1.00 and a 1-year high of $36.00. The stock has a market cap of $8.47 million, a price-to-earnings ratio of -0.28 and a beta of 0.84.

Institutional Investors Weigh In On CalciMedica

A hedge fund recently raised its stake in CalciMedica stock. Renaissance Technologies LLC grew its position in shares of CalciMedica Inc. (NASDAQ:CALC) by 45.0% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 128,075 shares of the company’s stock after purchasing an additional 39,775 shares during the period. Renaissance Technologies LLC owned 0.81% of CalciMedica worth $69,000 at the end of the most recent quarter.

CalciMedica Company Profile

CalciMedica, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for serious inflammatory and immune-mediated diseases. The company’s research centers on calcium release-activated calcium (CRAC) channels, which help regulate immune-cell activation and inflammatory responses. CalciMedica’s lead product candidate is zelnecirnon, formerly known as Auxora or CM4620. It is an investigational, selective CRAC channel inhibitor being evaluated as a potential treatment for acute inflammatory conditions, including severe acute pancreatitis and associated organ injury.